Use of salmeterol with and without concurrent use of inhaled corticosteroids and the risk of asthma-related hospitalization among patients with asthma*

@article{Wang2008UseOS,
  title={Use of salmeterol with and without concurrent use of inhaled corticosteroids and the risk of asthma-related hospitalization among patients with asthma*},
  author={M. Wang and G. Skrepnek and E. Armstrong and D. Sherrill and R. Harris and Cheng-Liang Tsai and D. Malone},
  journal={Current Medical Research and Opinion},
  year={2008},
  volume={24},
  pages={859 - 867}
}
ABSTRACT Rationale: Studies evaluating the safety of salmeterol are inconclusive, which might be the result from not taking into account the impact of concomitant inhaled corticosteroids (ICS). Objective: To study whether salmeterol use with and without concomitant ICS, respectively, was associated with an increased risk of asthma-related hospitalizations among patients with asthma. Methods: A case-control study nested within a cohort of patients with asthma, identified in the year 2000, over a… Expand
8 Citations
Update on the safety of long-acting beta-agonists in combination with inhaled corticosteroids for the treatment of asthma.
  • 11
Salmeterol/Fluticasone Propionate
  • 18
  • Highly Influenced

References

SHOWING 1-10 OF 38 REFERENCES
Asthma hospitalization risk and costs for patients treated with fluticasone propionate vs montelukast.
  • 23
Risk of emergency care, hospitalization, and ICU stays for acute asthma among recipients of salmeterol.
  • 48
A cohort analysis of excess mortality in asthma and the use of inhaled beta-agonists.
  • 334
Bronchodilator treatment and deaths from asthma: case-control study
  • 114
  • PDF
...
1
2
3
4
...